ClinConnect ClinConnect Logo
Search / Trial NCT06518291

COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMEN

Launched by SHALAMAR INSTITUTE OF HEALTH SCIENCES · Jul 18, 2024

Trial Information

Current as of August 25, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is designed to compare two antibiotics, nitrofurantoin and fosfomycin, to see which one works better for treating urinary tract infections (UTIs) in women. Both medications are commonly used for this purpose, but there hasn't been a recent direct comparison of their effectiveness. Women aged 18 and older who are experiencing symptoms of a lower UTI, like pain while urinating or needing to urinate frequently, may be eligible to participate. They would also need to have a positive urine test that indicates a UTI.

Participants in the trial can expect to receive one of the two antibiotics and will be monitored for their symptoms and overall response to the treatment. It’s important to note that certain individuals, such as pregnant or breastfeeding women, those with more severe infections, and those with specific health conditions, will not be able to join the study. This trial aims to provide clearer information on how these two medications stack up against each other, which can help doctors make better treatment choices for women with UTIs.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Adult women aged 18 years and older presenting with at least 1 symptom of lower UTI such as dysuria, urgency, frequency, or suprapubic tenderness and a urine dipstick test result positive for either nitrites or leukocyte esterase. Confirmed UTI will require the presence of at least 1 of the 4 urinary symptoms required for inclusion and a positive urine culture (≥103 cfu/mL). 21
  • Exclusion Criteria:
  • 1) Pregnancy and lactation 2) Suspected upper UTI (presence of fever, chills, or flank pain) 3) Antibiotic use or any symptoms consistent with UTI in the preceding 4 weeks 4) Indwelling urinary catheter or otherwise complicated UTI 5) Immunosuppression (untreated infection with HIV, ongoing chemotherapy or radiation therapy, use of high-dose corticosteroids or other immunosuppressive medication) 6) Renal insufficiency (creatinine clearance \<30 mL/min).

About Shalamar Institute Of Health Sciences

Shalamar Institute of Health Sciences is a leading healthcare organization dedicated to advancing medical research and clinical trials. With a commitment to improving patient outcomes and enhancing healthcare practices, the institute collaborates with a diverse array of stakeholders, including healthcare professionals, researchers, and regulatory bodies. By fostering innovation and adhering to the highest ethical standards, Shalamar Institute of Health Sciences aims to contribute significantly to the scientific community and the development of new therapeutic interventions. Its state-of-the-art facilities and experienced team provide a robust environment for conducting rigorous clinical trials that address pressing health challenges.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported